The role of whole-body imaging in the diagnosis, staging, and follow-up of multiple myeloma

Seminars in Musculoskeletal Radiology

Volumn 14, Issue 1, 2010, Pages 37-46

  Shortt, Conor P ^a   Carty, Fiona ^b   Murray, John G ^c  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b CAPPAGH NATIONAL ORTHOPAEDIC HOSPITAL   (Ireland)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Fluorodeoxyglucose F18; MRI; Multiple myeloma; Positron emission; Tomographyemission computed; Tomographyx ray computed; Total body

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; REVIEW; SCINTISCANNING; WHOLE BODY IMAGING;

HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 77949503368     PISSN: 10897860     EISSN: 1098898X     Source Type: Journal    
DOI: 10.1055/s-0030-1248705     Document Type: Article

References (44)

1. Parkin D M., Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 (2) 74-108
2. Durie B G., Kyle R A., Belch A et al, Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003 4 (6) 379-398
3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003 121 (5) 749-757
4. Dimopoulos M, Terpos E, Comenzo R L. et al, IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009 23 (9) 1545-1556
5. D'Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007 137 (1) 49-63
6. Durie B G., Salmon S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975 36 (3) 842-854
7. Durie B G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006 42 (11) 1539-1543
8. Richardson P G., Sonneveld P, Schuster M W. et al, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005 352 (24) 2487-2498
9. Mulligan M, Smith S, Talmi D. Whole body radiography for bone survey screening of cancer and myeloma patients. Cancer Invest 2008 26 (9) 916-922
10. Dinter D J., Neff W K., Klaus J et al. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Ann Hematol 2009 88 (5) 457-464
11. Baur A, Stbler A, Nagel D et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002 95 (6) 1334-1345
12. Tertti R, Alanen A, Remes K. The value of magnetic resonance imaging in screening myeloma lesions of the lumbar spine. Br J Haematol 1995 91 (3) 658-660
13. Gleeson T G., Moriarty J, Shortt C P. et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 2009 38 (3) 225-236
14. Mahnken A H., Wildberger J E., Gehbauer G et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002 178 (6) 1429-1436
15. Horger M, Kanz L, Denecke B et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007 109 (8) 1617-1626
16. Baur-Melnyk A, Buhmann S, Becker C et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008 190 (4) 1097-1104
17. Moulopoulos L A., Dimopoulos M A., Alexanian R, Leeds N E., Libshitz H I. Multiple myeloma: MR patterns of response to treatment. Radiology 1994 193 (2) 441-446
18. Rahmouni A, Divine M, Mathieu D et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol 1993 160 (5) 1053-1057
19. Horger M, Claussen C D., Bross-Bach U et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 2005 54 (2) 289-297
20. Antoch G, Vogt F M., Freudenberg L S. et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003 290 (24) 3199-3206
21. Baur-Melnyk A, Buhmann S, Drr H R., Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005 55 (1) 56-63
22. Hargaden G, O'Connell M, Kavanagh E, Powell T, Ward R, Eustace S. Current concepts in whole-body imaging using turbo short tau inversion recovery MR imaging. AJR Am J Roentgenol 2003 180 (1) 247-252
23. Johnston C, Brennan S, Ford S, Eustace S. Whole body MR imaging: applications in oncology. Eur J Surg Oncol 2006 32 (3) 239-246
24. Lecouvet F E., Vande Berg B C., Malghem J, Maldague B E. Magnetic resonance and computed tomography imaging in multiple myeloma. Semin Musculoskelet Radiol 2001 5 (1) 43-55
25. Weininger M, Lauterbach B, Knop S et al. Whole-body MRI of multiple myeloma: comparison of different MRI sequences in assessment of different growth patterns. Eur J Radiol 2009 69 (2) 339-345
26. Buerle T, Hillengass J, Fechtner K et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 2009 252 (2) 477-485
27. Baur A, Stbler A, Bartl R, Lamerz R, Reiser M. Infiltration patterns of plasmacytomas in magnetic resonance tomography [in German]. Rofo 1996 164 (6) 457-463
28. Shortt C P., Gleeson T G., Breen K A. et al. Whole-body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 2009 192 (4) 980-986
29. Moulopoulos L A., Dimopoulos M A. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997 90 (6) 2127-2147
30. Zamagni E, Nanni C, Patriarca F et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007 92 (1) 50-55
31. Schirrmeister H, Bommer M, Buck A K. et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002 29 (3) 361-366
32. Mileshkin L, Blum R, Seymour J F., Patrikeos A, Hicks R J., Prince H M. A comparison of fluorine-18 fluoro-deoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma. Eur J Haematol 2004 72 (1) 32-37
33. Bredella M A., Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005 184 (4) 1199-1204
34. Orchard K, Barrington S, Buscombe J, Hilson A, Prentice H G., Mehta A. Fluorodeoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol 2002 117 (1) 133-135
35. Gavish I, Bennett M, Israel O, Bar-Shalom R. 2-[18] fluoro-2-deoxy-D- glucose positron emission tomography imaging in non-secretory multiple myeloma. Br J Haematol 2003 123 (4) 566
36. Salaun P Y., Gastinne T, Frampas E, Bodet-Milin C, Moreau P, Bodr-Kraeber F. FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma. Haematologica 2008 93 (8) 1269-1271
37. Nanni C, Zamagni E, Farsad M et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 2006 33 (5) 525-531
38. Durie B G., Waxman A D., D'Agnolo A, Williams C M. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 2002 43 (11) 1457-1463
39. Wiesenthal A A., Nguyen B D. F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions. Clin Nucl Med 2007 32 (10) 797-801
40. Jadvar H, Conti P S. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol 2002 31 (12) 690-694
41. Villa G, Balleari E, Carletto M et al. Staging and therapy monitoring of multiple myeloma by 99mTc-sestamibi scintigraphy: a five year single center experience. J Exp Clin Cancer Res 2005 24 (3) 355-361
42. Tirovola E B., Biassoni L, Britton K E., Kaleva N, Kouykin V, Malpas J S. The use of 99mTc-MIBI scanning in multiple myeloma. Br J Cancer 1996 74 (11) 1815-1820
43. Balleari E, Villa G, Garr S et al. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haematologica 2001 86 (1) 78-84
44. Mirzaei S, Filipits M, Keck A et al. Comparison of technetium-99m-MIBI imaging with MRI for detection of spine involvement in patients with multiple myeloma. BMC Nucl Med 2003 3 (1) 2